Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250276
Status:
COMPLETED
Last Update Posted:
2020-01-02
First Post:
2005-11-07
Brief Title:
Evaluation of the Immune Responses of GSK Biologicals HPV Vaccine Following Manufacturing Process Adaptation
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Assess Lot-to-lot Consistency of GSK Biologicals HPV-1618 L1AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 016-mth Schedule in Healthy Female Subjects 18-25 y
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer Indeed the infection of the cervix by certain oncogenic types of HPV if not cleared can lead over time to cervical cancer in women This study will compare the immune response induced by different lots of the HPV-1618 L1AS04 vaccine following adjustments to the manufacturing process
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-001667-58 | EUDRACT_NUMBER | None | None |